Novartis Remibrutinib Cuts Annualized MS Relapse Rates by 31-35% Versus Aubagio in Phase 3 Trials

The REMODEL-1 and REMODEL-2 studies enrolled patients with relapsing MS and compared once-daily oral remibrutinib against teriflunomide (Aubagio). Primary endpoint was annualized relapse rate over approximately two years. Absolute rates fell to roughly one relapse every 13 years on remibrutinib. The drug also met secondary MRI lesion endpoints, consistent with reduced inflammatory activity.

Roche’s fenebrutinib previously demonstrated >50% relapse reduction versus the same comparator, yet remibrutinib’s BTK-inhibitor profile showed fewer liver enzyme elevations and no major cardiac signals in the presented data. This cleaner safety margin could offset modest efficacy differences when neurologists weigh options for patients intolerant to higher-efficacy agents.

Market positioning will depend on long-term disability progression data and real-world persistence. Oral convenience plus differentiated tolerability may carve a niche between moderate- and high-efficacy MS therapies, especially if post-marketing studies confirm low infection rates.

Regulatory filings are expected in 2026; FDA and EMA decisions will hinge on pooled safety databases exceeding 2,000 patient-years and confirmation that relapse reduction translates into sustained EDSS stability.